Carriage of serogroup W-135, ET-37 meningococci in The Gambia: Implications for immunisation policy?

Jenny M. MacLennan, Rachel Urwin, Steven Obaro, David Griffiths, Brian Greenwood, Martin C.J. Maiden

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

We found high levels of symptomless carriage of a hyperinvasive Neisseria meningitidis strain (electrophoretic type 37 [ET-37], serogroup W-135) during a vaccine trial in Gambian children in 1996. Serogroup C, ET-37 complex meningococci cause 30-40% of meningococcal disease in countries such as the UK, and have a point prevalence of 0.5-1.0%. The recent Haj-associated spread of serogroup W-135, ET-37 complex meningococci, which has been accompanied by numerous secondary cases, might be explained by the apparently raised carriage rates reported here.

Original languageEnglish (US)
Number of pages1
JournalLancet
Volume356
Issue number9235
DOIs
StatePublished - Sep 23 2000

Fingerprint

Gambia
Neisseria meningitidis
Immunization
Vaccines
Serogroup

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Carriage of serogroup W-135, ET-37 meningococci in The Gambia : Implications for immunisation policy? / MacLennan, Jenny M.; Urwin, Rachel; Obaro, Steven; Griffiths, David; Greenwood, Brian; Maiden, Martin C.J.

In: Lancet, Vol. 356, No. 9235, 23.09.2000.

Research output: Contribution to journalArticle

MacLennan, Jenny M. ; Urwin, Rachel ; Obaro, Steven ; Griffiths, David ; Greenwood, Brian ; Maiden, Martin C.J. / Carriage of serogroup W-135, ET-37 meningococci in The Gambia : Implications for immunisation policy?. In: Lancet. 2000 ; Vol. 356, No. 9235.
@article{e84849029a3f4b4dbd7659f403d4f2c8,
title = "Carriage of serogroup W-135, ET-37 meningococci in The Gambia: Implications for immunisation policy?",
abstract = "We found high levels of symptomless carriage of a hyperinvasive Neisseria meningitidis strain (electrophoretic type 37 [ET-37], serogroup W-135) during a vaccine trial in Gambian children in 1996. Serogroup C, ET-37 complex meningococci cause 30-40{\%} of meningococcal disease in countries such as the UK, and have a point prevalence of 0.5-1.0{\%}. The recent Haj-associated spread of serogroup W-135, ET-37 complex meningococci, which has been accompanied by numerous secondary cases, might be explained by the apparently raised carriage rates reported here.",
author = "MacLennan, {Jenny M.} and Rachel Urwin and Steven Obaro and David Griffiths and Brian Greenwood and Maiden, {Martin C.J.}",
year = "2000",
month = "9",
day = "23",
doi = "10.1016/S0140-6736(00)02734-3",
language = "English (US)",
volume = "356",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9235",

}

TY - JOUR

T1 - Carriage of serogroup W-135, ET-37 meningococci in The Gambia

T2 - Implications for immunisation policy?

AU - MacLennan, Jenny M.

AU - Urwin, Rachel

AU - Obaro, Steven

AU - Griffiths, David

AU - Greenwood, Brian

AU - Maiden, Martin C.J.

PY - 2000/9/23

Y1 - 2000/9/23

N2 - We found high levels of symptomless carriage of a hyperinvasive Neisseria meningitidis strain (electrophoretic type 37 [ET-37], serogroup W-135) during a vaccine trial in Gambian children in 1996. Serogroup C, ET-37 complex meningococci cause 30-40% of meningococcal disease in countries such as the UK, and have a point prevalence of 0.5-1.0%. The recent Haj-associated spread of serogroup W-135, ET-37 complex meningococci, which has been accompanied by numerous secondary cases, might be explained by the apparently raised carriage rates reported here.

AB - We found high levels of symptomless carriage of a hyperinvasive Neisseria meningitidis strain (electrophoretic type 37 [ET-37], serogroup W-135) during a vaccine trial in Gambian children in 1996. Serogroup C, ET-37 complex meningococci cause 30-40% of meningococcal disease in countries such as the UK, and have a point prevalence of 0.5-1.0%. The recent Haj-associated spread of serogroup W-135, ET-37 complex meningococci, which has been accompanied by numerous secondary cases, might be explained by the apparently raised carriage rates reported here.

UR - http://www.scopus.com/inward/record.url?scp=0034706229&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034706229&partnerID=8YFLogxK

U2 - 10.1016/S0140-6736(00)02734-3

DO - 10.1016/S0140-6736(00)02734-3

M3 - Article

C2 - 11009146

AN - SCOPUS:0034706229

VL - 356

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9235

ER -